drug_type
RELEVANT_DRUG
intervention_type
Genetically engineered allogeneic cellular therapy (CAR T cells)
drug_description
Donor-derived memory T cells genetically engineered to express an NKG2D-based chimeric antigen receptor targeting stress-induced NKG2D ligands (MICA/MICB/ULBPs) on tumor cells, intended to trigger T-cell cytotoxicity and overcome immune evasion; administered intravenously with optional intratumoral injection after lymphodepleting conditioning.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous, Intratumoral
drug_mechanism_of_action
Donor-derived memory T cells are genetically engineered to express an NKG2D-based chimeric antigen receptor that recognizes stress-induced NKG2D ligands (MICA/MICB/ULBPs) on tumor cells, leading to CAR-mediated T-cell activation, cytokine release, and targeted cytotoxic killing, with the memory phenotype supporting persistence and the approach aiming to overcome tumor immune evasion.
drug_name
NKG2D-CAR memory T cell
nct_id_drug_ref
NCT06087341